Journal
CELLS
Volume 10, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/cells10123431
Keywords
immunoproteasome; benzoxazole-2-carbonitriles; bidentate covalent inhibitors; fragments; non-covalent recognition
Categories
Ask authors/readers for more resources
Constitutive- and immunoproteasomes are vital components of the protein homeostasis system. Selective inhibition of immunoproteasomes shows promise for treating various diseases, and two series of compounds targeting proteasomes have been described in this study. The compounds exhibit significant inhibitory activities against specific subunits of the proteasomes, highlighting their potential for developing selective immunoproteasome inhibitors or compounds targeting multiple subunits.
Constitutive- and immunoproteasomes are part of the ubiquitin-proteasome system (UPS), which is responsible for the protein homeostasis. Selective inhibition of the immunoproteasome offers opportunities for the treatment of numerous diseases, including inflammation, autoimmune diseases, and hematologic malignancies. Although several inhibitors have been reported, selective nonpeptidic inhibitors are sparse. Here, we describe two series of compounds that target both proteasomes. First, benzoxazole-2-carbonitriles as fragment-sized covalent immunoproteasome inhibitors are reported. Systematic substituent scans around the fragment core of benzoxazole-2-carbonitrile led to compounds with single digit micromolar inhibition of the beta 5i subunit. Experimental and computational reactivity studies revealed that the substituents do not affect the covalent reactivity of the carbonitrile warhead, but mainly influence the non-covalent recognition. Considering the small size of the inhibitors, this finding emphasizes the importance of the non-covalent recognition step in the covalent mechanism of action. As a follow-up series, bidentate inhibitors are disclosed, in which electrophilic heterocyclic fragments, i.e., 2-vinylthiazole, benzoxazole-2-carbonitrile, and benzimidazole-2-carbonitrile were linked to threonine-targeting (R)-boroleucine moieties. These compounds were designed to bind both the Thr1 and beta 5i-subunit-specific residue Cys48. However, inhibitory activities against (immuno)proteasome subunits showed that bidentate compounds inhibit the beta 5, beta 5i, beta 1, and beta 1i subunits with submicromolar to low-micromolar IC50 values. Inhibitory assays against unrelated enzymes showed that compounds from both series are selective for proteasomes. The presented nonpeptidic and covalent derivatives are suitable hit compounds for the development of either beta 5i-selective immunoproteasome inhibitors or compounds targeting multiple subunits of both proteasomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available